Cytokinetics (CYTK) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Cytokinetics (CYTK) over the past year, gaining 125.8% versus a loss of 22.4%. Over five years, KNSA leads with a +706.0% price change compared with +30.1% for CYTK. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $7.07 billion), about 1.0 times the size, while Cytokinetics is growing revenue faster (+376.6% vs +60.1%).
Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -891.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | KNSA |
|---|---|---|
| Share price | $50.78 | $93.90 |
| Market cap | $7.07B | $7.38B |
| 1-day change | -1.32% | +0.38% |
| YTD return | -20.08% | +127.62% |
| 1-year return | -22.40% | +125.82% |
| 5-year return | +30.11% | +705.97% |
| P/E ratio (TTM) | — | 71.13 |
| Forward P/E | — | 45.91 |
| EPS (TTM) | $-6.02 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $677.56M |
| Revenue growth (YoY) | +376.56% | +60.09% |
| Net income (latest FY) | $-784.96M | $59.01M |
| Gross margin | — | 88.54% |
| Operating margin | -695.44% | 11.40% |
| Net margin | -891.60% | 8.71% |
| 52-week high | $88.31 | $99.31 |
| 52-week low | $50.32 | $37.02 |
| Distance from 52-week high | -42.50% | -5.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +115.48% | +18.82% |
| Average volume | 2.02M | 664.53K |
| Shares outstanding | 139.30M | 48.84M |
| Employees | 673 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed CYTK by 148.2 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -891.6 cents for Cytokinetics.
- Cytokinetics grew revenue faster in its latest fiscal year (+376.56% vs +60.09%).
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
CYTK vs KNSA FAQ
Which is bigger, Cytokinetics or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $7.07B for Cytokinetics (CYTK).
Which stock has performed better over the past year, CYTK or KNSA?
KNSA returned +125.82% over the past 12 months, compared with -22.40% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.